Johnson & Johnson's ($JNJ) new Prezista formulation, a once-daily 800 mg pill, won approval from European regulators. The FDA gave its blessing to the new HIV drug in November. The original Prezista is set to lose exclusivity in 2017. Report
| Sponsored By: Intralinks | Publisher: October 31
The shift from fully-integrated pharmaceutical companies to the more externalized, networked model of R&D is increasingly prominent. This eBook looks into the need for secure, cloud-based platforms to share files and collaborate. Download today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!